FIS
ENGNW icon

FCPM III Services’s enGene Therapeutics Warrants ENGNW Stock Holding History

FCPM III Services’s Portfolio ENGNW Stock Details ENGNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$834K Hold
2,878,148
– – 0.11% 11
2026
Q1 		$7.28M Hold
2,878,148
– – 1.01% 10
2025
Q4 		$8.52M Hold
2,878,148
– – 1.12% 10
2025
Q3 		$2.07M Hold
2,878,148
– – 0.41% 9
2025
Q2 		$2.36M Hold
2,878,148
– – 0.64% 8
2025
Q1 		$1.73M Hold
2,878,148
– – 0.42% 7
2024
Q4 		$2.43M Hold
2,878,148
– – 0.41% 8
2024
Q3 		$6.04M Hold
2,878,148
– – 1.04% 6
2024
Q2 		$3.42M Hold
2,878,148
– – 0.51% 6
2024
Q1 		$15M Sell
2,878,148
-1,000,000
-26% -$3.05M 2.12% 5
2023
Q4 		$2.45M Buy
+3,878,148
New +$2.98M 0.72% 5

Other funds holding ENGNW

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $21.5B AUM 81.81% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.57B AUM 67.1% 1-Year Est. Return
CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

FCPM III Services's ENGNW Position: Q2 2026 in Review

FCPM III Services held its enGene Therapeutics Warrants (ENGNW) position steady in Q2 2026 at 2,878,148 shares worth $834K. The position accounts for 0.11% of the portfolio, ranked #11.

FCPM III Services first reported a position in ENGNW in Q4 2023 and has held it in 11 quarters since. The position peaked at $15M in Q1 2024. 11 funds tracked by Wall St. Rank hold ENGNW as of Q2 2026.

  • FCPM III Services held 2,878,148 shares of enGene Therapeutics Warrants worth $834K as of Q2 2026.
  • FCPM III Services left its enGene Therapeutics Warrants share count unchanged in Q2 2026.
  • enGene Therapeutics Warrants made up 0.11% of FCPM III Services's portfolio in Q2 2026, its #11 holding.
  • FCPM III Services first reported a position in enGene Therapeutics Warrants in Q4 2023 and has held it in 11 quarters since.
  • FCPM III Services's enGene Therapeutics Warrants position peaked at $15M in Q1 2024.
  • 11 funds tracked by Wall St. Rank held enGene Therapeutics Warrants as of Q2 2026.

Based on FCPM III Services's 13F filing for Q2 2026, filed 14 Aug 2026.